Trial Profile
A Phase 1 Dose Escalation Study of TTI-237 Administered Intravenously (IV) Once Weekly in Subjects With Advanced Malignant Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 23 Jul 2007
Price :
$35
*
At a glance
- Drugs Cevipabulin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Wyeth
- 11 Jan 2007 Status change
- 26 Nov 2005 New trial record.